Anti-glutamate transporter GLT-1 blocking peptide

Discontinued Product

Anti-glutamate transporter GLT-1 blocking peptide (Cat. No. 2128) has been withdrawn from sale for commercial reasons.
Cat.No. 2128 - Anti-glutamate transporter GLT-1 blocking peptide | [Cys]-Ala-Ala-Asn-Gly-Lys-Ser-Ala-Asp-Cys-Ser-Val-Glu-Glu-Glu-Pro-Trp-Lys-Arg-Glu-Lys
Description: Blocking peptide for anti-glutamate transporter GLT-1 (Cat. No. 2063)
Datasheet
Citations
Reviews
Literature

Biological Activity

Synthetic peptide ([C]-AANGKSADCSVEEEPWKREK) corresponding to C-terminal amino acids 554-573 of rat precursor glutamate transporter GLT-1 (Accession No. P31596) with a cysteine added at the N-terminus of the peptide. Used as an immunogen for anti-glutamate transporter GLT-1 (Cat. No. 2063).

Technical Data

M. Wt 2337.56
Formula C96H153N29O35S2
Sequence CAANGKSADCSVEEEPWKREK
Storage Desiccate at -20°C
Smiles [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References

References are publications that support the biological activity of the product.

Keywords: Anti-glutamate transporter GLT-1 blocking peptide, Anti-glutamate transporter GLT-1 blocking peptide supplier, anti-glutamate, transporter, GLT-1, EAAT, Excitatory, Amino, Acid, Transporters, Monoamine, Neurotransmitter, immunogen, blocking, peptides, Glutamate, 2128, Tocris Bioscience

Citations for Anti-glutamate transporter GLT-1 blocking peptide

Citations are publications that use Tocris products.

Currently there are no citations for Anti-glutamate transporter GLT-1 blocking peptide.

Reviews for Anti-glutamate transporter GLT-1 blocking peptide

There are currently no reviews for this product. Be the first to review Anti-glutamate transporter GLT-1 blocking peptide and earn rewards!

Have you used Anti-glutamate transporter GLT-1 blocking peptide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.